RCUS: Arcus Biosciences, Inc.
About
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Current Value
$14.471 Year Return
Current Value
$14.471 Year Return
Key Details
Market Cap
$1.33B
P/E Ratio
-4.6
1Y Stock Return
5.07%
1Y Revenue Growth
119.80%
Dividend Yield
0.00%
Price to Book
2.3
Strategies that include RCUS
Stock's related to RCUS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OUT | 47.94% | $3.11B | +52.98% | 6.41% |
| ALEC | 46.96% | $377.04M | -19.46% | 0.00% |
| ACLX | 46.47% | $4.74B | +69.19% | 0.00% |
| OCUL | 45.31% | $1.40B | +307.31% | 0.00% |
| G | 44.23% | $7.83B | +31.86% | 1.34% |
| PLRX | 43.98% | $778.32M | -9.55% | 0.00% |
| DNLI | 43.77% | $3.50B | +33.66% | 0.00% |
| RXRX | 43.51% | $1.80B | -4.13% | 0.00% |
| AMWD | 43.13% | $1.46B | +29.41% | 0.00% |
| MMI | 42.93% | $1.58B | +23.86% | 1.24% |
| ADMA | 42.63% | $4.88B | +423.60% | 0.00% |
| SNDX | 42.34% | $1.35B | +2.87% | 0.00% |
| TY | 42.12% | - | - | 3.32% |
| ALLO | 41.95% | $444.50M | -24.82% | 0.00% |
| OLP | 41.67% | $617.02M | +46.60% | 6.26% |
| ALEX | 41.55% | $1.41B | +18.14% | 4.59% |
| RMAX | 41.18% | $215.33M | +23.09% | 0.00% |
| CSV | 41.05% | $590.66M | +75.49% | 1.16% |
| RMR | 40.73% | $368.58M | -6.46% | 7.97% |
| SVC | 40.67% | $431.62M | -63.31% | 23.74% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PUBM | 0.01% | $739.82M | -2.82% | 0.00% |
| GPRK | 0.15% | $440.00M | -9.95% | 6.37% |
| LPLA | -0.19% | $23.55B | +38.13% | 0.38% |
| ACGL | -0.19% | $36.00B | +16.84% | 0.00% |
| LITB | 0.20% | $35.48M | -75.45% | 0.00% |
| CMG | -0.22% | $80.02B | +33.62% | 0.00% |
| RNR | 0.22% | $13.74B | +23.09% | 0.58% |
| TKC | -0.24% | $5.80B | +35.51% | 1.30% |
| NFE | 0.31% | $2.29B | -74.75% | 3.32% |
| JNPR | 0.35% | $11.61B | +30.55% | 2.49% |
| MNR | 0.37% | $1.66B | -10.71% | 15.90% |
| ATGE | 0.54% | $3.29B | +55.26% | 0.00% |
| MANU | 0.68% | $2.88B | -9.41% | 0.00% |
| NHTC | 0.79% | $61.83M | +0.19% | 14.81% |
| KR | -0.87% | $42.03B | +35.08% | 2.11% |
| CCEC | -0.89% | $1.02B | +28.03% | 3.26% |
| META | 0.93% | $1.42T | +66.51% | 0.27% |
| BCAN | -0.98% | $72.87M | -99.75% | 0.00% |
| FIVN | -1.04% | $2.83B | -49.23% | 0.00% |
| VIST | 1.16% | $4.75B | +67.10% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HUSA | -19.51% | $16.69M | -11.56% | 0.00% |
| FATBB | -9.99% | $81.94M | -12.91% | 11.69% |
| IMRN | -9.31% | $10.31M | -5.04% | 0.00% |
| OXBR | -9.02% | $19.05M | +178.18% | 0.00% |
| UUU | -8.74% | $4.97M | -41.89% | 0.00% |
| CBOE | -6.59% | $21.46B | +15.84% | 1.11% |
| BTCT | -6.35% | $42.61M | +353.33% | 0.00% |
| VSTA | -5.31% | $204.94M | -39.33% | 0.00% |
| BACK | -5.29% | $1.76M | -32.90% | 0.00% |
| NEUE | -5.20% | $40.93M | -34.13% | 0.00% |
| FAT | -4.90% | $89.30M | -11.53% | 10.73% |
| ASPS | -4.01% | $22.36M | -80.26% | 0.00% |
| PGR | -3.85% | $149.10B | +57.29% | 0.45% |
| MCK | -3.77% | $78.15B | +35.51% | 0.42% |
| DXCM | -3.65% | $29.25B | -31.28% | 0.00% |
| COR | -3.51% | $47.48B | +21.20% | 0.86% |
| TCTM | -3.49% | $8.10M | -42.99% | 0.00% |
| PULM | -3.41% | $19.83M | +202.98% | 0.00% |
| LTRN | -3.41% | $33.22M | -22.61% | 0.00% |
| CYD | -3.37% | $364.46M | -2.94% | 4.26% |
ETF's related to RCUS
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -33.82% | $388.04M | 1.43% |
| VIXY | -32.43% | $195.31M | 0.85% |
| USDU | -22.45% | $201.97M | 0.5% |
| TAIL | -18.57% | $67.98M | 0.59% |
| UUP | -13.78% | $309.25M | 0.77% |
| TPMN | -10.61% | $40.60M | 0.65% |
| CTA | -8.89% | $350.27M | 0.78% |
| EQLS | -7.36% | $76.08M | 1% |
| JUCY | -6.02% | $324.29M | 0.6% |
| KMLM | -5.48% | $353.87M | 0.9% |
| AGZD | -4.64% | $142.76M | 0.23% |
| KRBN | -4.39% | $242.47M | 0.85% |
| SOYB | -3.81% | $27.32M | 0.22% |
| CORN | -3.43% | $61.12M | 0.2% |
| HIGH | -1.87% | $302.78M | 0.51% |
| XHLF | -1.49% | $874.27M | 0.03% |
| DBO | -0.85% | $217.57M | 0.77% |
| BILZ | -0.18% | $563.02M | 0.14% |
| KCCA | -0.08% | $220.51M | 0.87% |
| CANE | 0.25% | $17.72M | 0.29% |
News
Yahoo
HAYWARD, Calif., November 19, 2024--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December:
Yahoo
HAYWARD, Calif., November 12, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 14,100 shares of the Company’s common stock at an exercise price per share of $17.85, which was the closing price on November 8, 2024, an
Yahoo
Arcus Biosciences, Inc. ( NYSE:RCUS ) defied analyst predictions to release its third-quarter results, which were ahead...
Yahoo
Arcus Biosciences Inc (RCUS) reports robust financial health and strategic advancements in late-stage trials, despite facing competitive and strategic challenges.
SeekingAlpha
The following slide deck was published by Arcus Biosciences, Inc.
SeekingAlpha
Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ETCompany ParticipantsPia Eaves - Vice President-Investor...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.